Wei-Fen Xie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Wei-Fen Xie has a total of 661 co-authors. Here are the top co-authors by number of shared publications:
Xin Zhang
Department of Gastroenterology, Changzheng Hospital, Naval Medical University, Shanghai, China
51 shared publicationsChen-Hong Ding
Department of Gastroenterology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China
33 shared publicationsShu-Qing Liu
Department of Gastroenterology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China
29 shared publicationsXin Zeng
Department of Gastroenterology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China
23 shared publicationsShi-Jie Chen
Drug Discovery and Design Center, CAS Key Laboratory of Receptor Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
22 shared publicationsCheng Luo
Drug Discovery and Design Center, Chinese Academy of Sciences Key Laboratory of Receptor Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
21 shared publications
Latest Publications
- Open Access
- 30 October 2026
- Published by The Korean Society of Neurogastroenterology and Motility in Journal of Neurogastroenterology and Motility
- Vol. 32 (4) , 644-654
Effects of Needleless Transcutaneous Electrical Acustimulation on Gastrointestinal Function Recovery After Multi-Level Lumbar Surgery: A Randomized Clinical Trial
Yuhao Song, Jian Wang, Wenyu Zhang, Tianxing Li, Yanan Mao, Jiande D. Z. Chen, Lei Liang, Weifen Xie, and Beifang Ning . J Neurogastroenterol Motil 2026;32:644-54. https://doi.org/10.5056/jnm25261
- 30 October 2026
- Published by The Korean Society of Neurogastroenterology and Motility in Journal of Neurogastroenterology and Motility
- Vol. 32 (4) , 644-654
Open AccessEffects of Needleless Transcutaneous Electrical Acustimulation on Gastrointestinal Function Recovery After Multi-Level Lumbar Surgery: A Randomized Clinical Trial
Yuhao Song, Jian Wang, Wenyu Zhang, Tianxing Li, Yanan Mao, Jiande D. Z. Chen, Lei Liang, Weifen Xie, and Beifang Ning . J Neurogastroenterol Motil 2026;32:644-54. https://doi.org/10.5056/jnm25261
- 5 September 2026
- Published by Wiley in Liver International
- Vol. 46 (10) , e70846
Inhibition of Acetylation Activity of p300/ CBP Ameliorates Hepatic Steatosis Through Downregulation of ACSL4
Background & Aims: Metabolic dysfunction–associated steatotic liver disease (MASLD) is the most prevalent chronic liver disorder, with few optimal pharmacotherapies. Ongoing studies are providing evidence that histone acetylation contributes to the progression of MASLD. This study investigated the alterations of specific histone acetylation sites in MASLD tissues and the effects of B029‐2, a small‐molecule inhibitor targeting p300/CBP acetylation activity, in mouse models of progressive fatty liver disease. Methods: The acetylation of H3K27/H3K18/H3K9 was assessed in liver samples from MASLD patients and mice. The effect of the B029‐2 in MASLD was assessed in MASLD models. A ChIP assay was conducted to investigate the epigenetic regulatory mechanism of ACSL4. Hepatic‐specific Acsl4‐knockout and overexpression mice were generated to validate the role of ACSL4 in MASLD. Results: We observed a significant increase in p300 HAT activity, p300/CBP‐induced H3K18ac and H3K27ac levels in MASLD and B029‐2 markedly reduced hepatic steatosis in vitro and in vivo. Transcriptome analysis revealed that B029‐2 inhibited the expression of genes in the triglyceride biosynthetic process and long‐chain fatty‐acyl‐CoA biosynthetic process. ChIP assay showed that H3K18ac, H3K27ac and p300 bind to the promoter region of ACSL4 , and their binding is reduced by B029‐2 treatment. AAV‐mediated hepatic‐specific overexpression of Acsl4 attenuated the effect of B029‐2 on MASLD in mice, while hepatic‐specific Acsl4‐deficient in mice blocked the effect of B029‐2. Conclusions: p300/CBP‐mediated H3K18ac and H3K27ac regulate ACSL4‐dependent lipid biosynthesis in MASLD and might be a potential therapeutic target for the treatment of MASLD.
- 5 September 2026
- Published by Wiley in Liver International
- Vol. 46 (10) , e70846
Inhibition of Acetylation Activity of p300/ CBP Ameliorates Hepatic Steatosis Through Downregulation of ACSL4
Background & Aims: Metabolic dysfunction–associated steatotic liver disease (MASLD) is the most prevalent chronic liver disorder, with few optimal pharmacotherapies. Ongoing studies are providing evidence that histone acetylation contributes to the progression of MASLD. This study investigated the alterations of specific histone acetylation sites in MASLD tissues and the effects of B029‐2, a small‐molecule inhibitor targeting p300/CBP acetylation activity, in mouse models of progressive fatty liver disease. Methods: The acetylation of H3K27/H3K18/H3K9 was assessed in liver samples from MASLD patients and mice. The effect of the B029‐2 in MASLD was assessed in MASLD models. A ChIP assay was conducted to investigate the epigenetic regulatory mechanism of ACSL4. Hepatic‐specific Acsl4‐knockout and overexpression mice were generated to validate the role of ACSL4 in MASLD. Results: We observed a significant increase in p300 HAT activity, p300/CBP‐induced H3K18ac and H3K27ac levels in MASLD and B029‐2 markedly reduced hepatic steatosis in vitro and in vivo. Transcriptome analysis revealed that B029‐2 inhibited the expression of genes in the triglyceride biosynthetic process and long‐chain fatty‐acyl‐CoA biosynthetic process. ChIP assay showed that H3K18ac, H3K27ac and p300 bind to the promoter region of ACSL4 , and their binding is reduced by B029‐2 treatment. AAV‐mediated hepatic‐specific overexpression of Acsl4 attenuated the effect of B029‐2 on MASLD in mice, while hepatic‐specific Acsl4‐deficient in mice blocked the effect of B029‐2. Conclusions: p300/CBP‐mediated H3K18ac and H3K27ac regulate ACSL4‐dependent lipid biosynthesis in MASLD and might be a potential therapeutic target for the treatment of MASLD.
- 31 May 2026
- Published by Wiley in Journal of Digestive Diseases
- Vol. 27 (5-6) , 214-224
Multidimensional Optimization of Small Bowel Capsule Endoscopy With Transcutaneous Electrical Acustimulation: A Randomized Controlled Trial
Objectives: To evaluate whether transcutaneous electrical acustimulation (TEA) during bowel preparation for small bowel capsule endoscopy (SBCE) can reduce the incidence of gastrointestinal adverse events (AEs), shorten gastric transit time (GTT), improve small bowel visualization quality, and enhance patient acceptability. Methods: We prospectively enrolled outpatients scheduled for SBCE during December 2023 and March 2025. The participants were randomly allocated to receive either TEA at bilateral ST36 acupoints or sham stimulation (control) at non‐acupoints during bowel preparation with split‐dose polyethylene glycol. The primary outcome was the overall incidence of gastrointestinal AEs. Secondary outcomes included AE severity, small bowel visualization quality, GTT, and lesion detection rate, among others. Results: A total of 39 participants completed the trial. Compared with the control group, TEA significantly reduced the overall incidence of gastrointestinal AEs during bowel preparation ( p = 0.004), with particularly notable reductions in nausea and abdominal bloating. The overall severity of AEs was also markedly lower in the TEA group ( p < 0.001). Furthermore, TEA significantly improved visualization quality scores for both the entire ( p = 0.003) and distal small bowel ( p = 0.030). GTT was significantly shorter in the TEA group ( p < 0.001), and patient‐reported scores for comfort ( p = 0.027) and acceptability ( p = 0.015) were significantly higher in the TEA group. Conclusions: TEA during SBCE bowel preparation significantly reduces gastrointestinal AEs, enhances small bowel visualization quality, and accelerates GTT. TEA is a safe and well‐tolerated intervention, making it a promising adjunct to optimize SBCE.
- 31 May 2026
- Published by Wiley in Journal of Digestive Diseases
- Vol. 27 (5-6) , 214-224
Multidimensional Optimization of Small Bowel Capsule Endoscopy With Transcutaneous Electrical Acustimulation: A Randomized Controlled Trial
Objectives: To evaluate whether transcutaneous electrical acustimulation (TEA) during bowel preparation for small bowel capsule endoscopy (SBCE) can reduce the incidence of gastrointestinal adverse events (AEs), shorten gastric transit time (GTT), improve small bowel visualization quality, and enhance patient acceptability. Methods: We prospectively enrolled outpatients scheduled for SBCE during December 2023 and March 2025. The participants were randomly allocated to receive either TEA at bilateral ST36 acupoints or sham stimulation (control) at non‐acupoints during bowel preparation with split‐dose polyethylene glycol. The primary outcome was the overall incidence of gastrointestinal AEs. Secondary outcomes included AE severity, small bowel visualization quality, GTT, and lesion detection rate, among others. Results: A total of 39 participants completed the trial. Compared with the control group, TEA significantly reduced the overall incidence of gastrointestinal AEs during bowel preparation ( p = 0.004), with particularly notable reductions in nausea and abdominal bloating. The overall severity of AEs was also markedly lower in the TEA group ( p < 0.001). Furthermore, TEA significantly improved visualization quality scores for both the entire ( p = 0.003) and distal small bowel ( p = 0.030). GTT was significantly shorter in the TEA group ( p < 0.001), and patient‐reported scores for comfort ( p = 0.027) and acceptability ( p = 0.015) were significantly higher in the TEA group. Conclusions: TEA during SBCE bowel preparation significantly reduces gastrointestinal AEs, enhances small bowel visualization quality, and accelerates GTT. TEA is a safe and well‐tolerated intervention, making it a promising adjunct to optimize SBCE.
- 12 May 2026
- Published by Elsevier in Journal of Hepatology
- Vol. 85 (3) , 515-527
Rifaximin ameliorates cirrhotic portal hypertension through suppression of microbiome-derived deoxycholic acid
- 12 May 2026
- Published by Elsevier in Journal of Hepatology
- Vol. 85 (3) , 515-527
Rifaximin ameliorates cirrhotic portal hypertension through suppression of microbiome-derived deoxycholic acid
- Open Access
- 26 April 2026
- Published by SAGE Publications in Therapeutic Advances in Gastroenterology
- Vol. 19
Efficacy and safety of glucocorticoids for acute drug-induced liver injury with hyperbilirubinemia: protocol of a multicenter randomized controlled trial
Background: Drug-induced liver injury (DILI) can lead to potentially fatal complications, such as acute liver failure and even death. In clinical practice, glucocorticoids have been considered in some cases of DILI, especially those with hyperbilirubinemia. However, the available evidence remains controversial and its quality is also very limited. Objectives: To explore the efficacy and safety of glucocorticoids in patients with acute DILI and hyperbilirubinemia. Design: An open-label, multicenter, randomized controlled trial (RCT). Methods and analysis: Overall, 232 patients with acute DILI with hyperbilirubinemia will be enrolled, and then, randomly assigned at a ratio of 1:1 to the conventional treatment alone or combined with glucocorticoids groups. The primary endpoint is the improvement of DILI, which is defined as total bilirubin level decreased by 50% after treatment, at the 2nd week. Secondary endpoints include the improvement of DILI at the 4th week and rates of progressive liver injury, liver failure, liver transplantation, survival, and adverse events. As for exploratory endpoints, we will also identify the beneficial population and assess the changes of inflammatory factors following glucocorticoids treatment. Ethics: The study has been approved by the Medical Ethical Committee of the General Hospital of Northern Theater Command (ethical approval number Y2024-226) as well as 11 other participating centers. Discussion: This RCT will provide solid evidence to clarify the benefits of glucocorticoids in patients with acute DILI and hyperbilirubinemia. Trial registration: ClinicalTrials.gov identifier: NCT06922669.
- 26 April 2026
- Published by SAGE Publications in Therapeutic Advances in Gastroenterology
- Vol. 19
Open AccessEfficacy and safety of glucocorticoids for acute drug-induced liver injury with hyperbilirubinemia: protocol of a multicenter randomized controlled trial
Background: Drug-induced liver injury (DILI) can lead to potentially fatal complications, such as acute liver failure and even death. In clinical practice, glucocorticoids have been considered in some cases of DILI, especially those with hyperbilirubinemia. However, the available evidence remains controversial and its quality is also very limited. Objectives: To explore the efficacy and safety of glucocorticoids in patients with acute DILI and hyperbilirubinemia. Design: An open-label, multicenter, randomized controlled trial (RCT). Methods and analysis: Overall, 232 patients with acute DILI with hyperbilirubinemia will be enrolled, and then, randomly assigned at a ratio of 1:1 to the conventional treatment alone or combined with glucocorticoids groups. The primary endpoint is the improvement of DILI, which is defined as total bilirubin level decreased by 50% after treatment, at the 2nd week. Secondary endpoints include the improvement of DILI at the 4th week and rates of progressive liver injury, liver failure, liver transplantation, survival, and adverse events. As for exploratory endpoints, we will also identify the beneficial population and assess the changes of inflammatory factors following glucocorticoids treatment. Ethics: The study has been approved by the Medical Ethical Committee of the General Hospital of Northern Theater Command (ethical approval number Y2024-226) as well as 11 other participating centers. Discussion: This RCT will provide solid evidence to clarify the benefits of glucocorticoids in patients with acute DILI and hyperbilirubinemia. Trial registration: ClinicalTrials.gov identifier: NCT06922669.
- Open Access
- 4 April 2026
- Published by Walter de Gruyter GmbH in Journal of Translational Internal Medicine
- Vol. 14 (3) , 481-484
Cirrhotic portal hypertension treated with a 5-hydroxytryptamine receptor 1A antagonist
- 4 April 2026
- Published by Walter de Gruyter GmbH in Journal of Translational Internal Medicine
- Vol. 14 (3) , 481-484
Open AccessCirrhotic portal hypertension treated with a 5-hydroxytryptamine receptor 1A antagonist
- Open Access
- 12 February 2026
- Published by Elsevier in SSRN Electronic Journal
Rifaximin Alleviates MASH by Suppressing Deoxycholic Acid-Triggered Macrophage-Hepatocyte Dialogue
Rifaximin ameliorates metabolic dysfunction-associated steatohepatitis (MASH) in preclinical models; however, its underlying molecular mechanisms and therapeutic potential in the clinic remain incompletely defined. Here, we demonstrate that rifaximin alleviates MASH by reducing intestinal deoxycholic acid (DCA), a secondary bile acid that directly activates S1PR2 on MoMFs. DCA-S1PR2 signaling promotes MoMF recruitment to steatotic livers and induces secretion of MD-1 that suppresses hepatocyte Hnf1α through activation of TLR4. The therapeutic efficacy of rifaximin is dependent on restoration of hepatic Hnf1α expression, whereas hepatocyte Hnf1α deficiency perpetuates a feed-forward loop of Ccl2-driven MoMF recruitment. In a proof-of-concept clinical trial, rifaximin treatment led to rapid and progressive improvements in hepatic steatosis in patients with MASLD. Therapeutic responses were correlated with the reductions in fecal and serum DCA levels and circulating MD-1. Our findings define a pathogenic DCA-driven macrophage-hepatocyte crosstalk underlying MASH progression and establish rifaximin as a promising, mechanism-based therapeutic strategy for MASH.
- 12 February 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessRifaximin Alleviates MASH by Suppressing Deoxycholic Acid-Triggered Macrophage-Hepatocyte Dialogue
Rifaximin ameliorates metabolic dysfunction-associated steatohepatitis (MASH) in preclinical models; however, its underlying molecular mechanisms and therapeutic potential in the clinic remain incompletely defined. Here, we demonstrate that rifaximin alleviates MASH by reducing intestinal deoxycholic acid (DCA), a secondary bile acid that directly activates S1PR2 on MoMFs. DCA-S1PR2 signaling promotes MoMF recruitment to steatotic livers and induces secretion of MD-1 that suppresses hepatocyte Hnf1α through activation of TLR4. The therapeutic efficacy of rifaximin is dependent on restoration of hepatic Hnf1α expression, whereas hepatocyte Hnf1α deficiency perpetuates a feed-forward loop of Ccl2-driven MoMF recruitment. In a proof-of-concept clinical trial, rifaximin treatment led to rapid and progressive improvements in hepatic steatosis in patients with MASLD. Therapeutic responses were correlated with the reductions in fecal and serum DCA levels and circulating MD-1. Our findings define a pathogenic DCA-driven macrophage-hepatocyte crosstalk underlying MASH progression and establish rifaximin as a promising, mechanism-based therapeutic strategy for MASH.
- 3 November 2025
- Published by Springer Nature in Hepatology International
- Vol. 20 (3) , 775-789
SOX9 promotes hepatocyte proliferation via upregulating TGF-α expression during liver regeneration
Background The liver possesses a remarkable capacity for regeneration. Previous studies have shown that SOX9/HNF4α double-positive hepatocytes play a role in chronic liver injury. Furthermore, the deletion of HNF4α results in prolonged hepatocyte proliferation following partial hepatectomy. However, the precise role of SOX9 in liver regeneration remains poorly understood. Methods We established acute liver injury models using standard partial hepatectomy (sHx), extended partial hepatectomy (eHx), and intraperitoneal injection of carbon tetrachloride (CCl4). To investigate the interplay between HNF4α and SOX9, we employed hepatocyte-specific Hnf4α knockout (Hnf4αHKO) and Sox9 knockout (Sox9HKO) mice. We assessed how SOX9 influenced liver regeneration in Sox9HKO and SOX9-overexpressing (Sox9HOE) mice. Results Our study found that SOX9 expression was increased, while HNF4α expression decreased in the priming phase of acute liver injury. HNF4α suppressed SOX9 expression by upregulating miR-124/381 in hepatocytes. Deletion of SOX9 in hepatocytes resulted in a reduced liver-to-body weight ratio and impaired hepatocyte proliferation in both sHx- and CCl4-treated mice. Conversely, hepatocyte-specific SOX9 overexpression improved survival rates in eHx-treated mice. Single-nucleus RNA sequencing of liver tissue and bulk RNA sequencing of hepatocytes from sHx-treated Sox9HKO mice revealed that SOX9 upregulated TGF-α expression in hepatocytes. Co-culture experiments further indicated that SOX9 overexpression enhanced the hepatocyte proliferation by promoting TGF-α secretion. Importantly, inhibiting TGF-α-induced EGFR activation partially reduced the pro-proliferative effects of SOX9 on hepatocytes and the survival rates by SOX9 overexpression in eHx-treated mice. Conclusions Our findings revealed that HNF4α negatively regulates SOX9 and demonstrated that SOX9 promotes hepatocyte proliferation by upregulating TGF-α levels, ultimately enhancing liver regeneration. Graphical abstract
- 3 November 2025
- Published by Springer Nature in Hepatology International
- Vol. 20 (3) , 775-789
SOX9 promotes hepatocyte proliferation via upregulating TGF-α expression during liver regeneration
Background The liver possesses a remarkable capacity for regeneration. Previous studies have shown that SOX9/HNF4α double-positive hepatocytes play a role in chronic liver injury. Furthermore, the deletion of HNF4α results in prolonged hepatocyte proliferation following partial hepatectomy. However, the precise role of SOX9 in liver regeneration remains poorly understood. Methods We established acute liver injury models using standard partial hepatectomy (sHx), extended partial hepatectomy (eHx), and intraperitoneal injection of carbon tetrachloride (CCl4). To investigate the interplay between HNF4α and SOX9, we employed hepatocyte-specific Hnf4α knockout (Hnf4αHKO) and Sox9 knockout (Sox9HKO) mice. We assessed how SOX9 influenced liver regeneration in Sox9HKO and SOX9-overexpressing (Sox9HOE) mice. Results Our study found that SOX9 expression was increased, while HNF4α expression decreased in the priming phase of acute liver injury. HNF4α suppressed SOX9 expression by upregulating miR-124/381 in hepatocytes. Deletion of SOX9 in hepatocytes resulted in a reduced liver-to-body weight ratio and impaired hepatocyte proliferation in both sHx- and CCl4-treated mice. Conversely, hepatocyte-specific SOX9 overexpression improved survival rates in eHx-treated mice. Single-nucleus RNA sequencing of liver tissue and bulk RNA sequencing of hepatocytes from sHx-treated Sox9HKO mice revealed that SOX9 upregulated TGF-α expression in hepatocytes. Co-culture experiments further indicated that SOX9 overexpression enhanced the hepatocyte proliferation by promoting TGF-α secretion. Importantly, inhibiting TGF-α-induced EGFR activation partially reduced the pro-proliferative effects of SOX9 on hepatocytes and the survival rates by SOX9 overexpression in eHx-treated mice. Conclusions Our findings revealed that HNF4α negatively regulates SOX9 and demonstrated that SOX9 promotes hepatocyte proliferation by upregulating TGF-α levels, ultimately enhancing liver regeneration. Graphical abstract
- Open Access
- 1 November 2025
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 16 (2) , 913-929
Blocking TRIM47-mediated HNF4α degradation suppresses hepatocellular carcinoma progression
- 1 November 2025
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 16 (2) , 913-929
Open AccessBlocking TRIM47-mediated HNF4α degradation suppresses hepatocellular carcinoma progression